2-HG spectroscopy in low grade glioma patients treated with vorasidenib - a pilot study

2-HG spectroscopy in low grade glioma patients treated with vorasidenib - a pilot study - 2-HG MRS and vorasidenib

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56925

Enrollment

Registered

2024-07-25

Start date

2024-08-01

Completion date

Unknown

Last updated

2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

low grade brain tumor Low grade glioma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Low grade glioma patients (WHO II), either suspected or histologically proven. treated with vorasidenib Signed informed consent.

Exclusion criteria

Exclusion criteria: Age

Design outcomes

Primary

Measure	Time frame
Primary outcome is the association between preoperative 2-HG levels (measured with MR spectroscopy) an progression free time in patients with low grade gliomas that are treated with Vorasidenib. Progression is defined according to the RANO LGG criteria.	—

Countries

Netherlands

Outcome results